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A B S T R A C T
MS is a chronic, increasingly disabling disease whose long-term outcomes determine the key social, medical and eco-
nomic impact of this disease. Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are prescribed to delay dis-
ease progression and to protect a patient’s functional capability. The concepts of escalation and induction immuno-
therapy in MS represent different therapeutic strategies for the treatment of MS. Both strategies may be valuable options
for patients starting on DMT, however, induction therapy mainly focuses on patients with very aggressive course of MS
from the onset. Using a patient unique approach to selection of treatment, MS can be effectively control disease and may
delay or even prevent the development of secondary progressive MS.
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Introduction
When a patient is experiencing the initial symptoms
of multiple sclerosis (MS), he or she is at a mean age of 30
years and will usually live for another 3 to 4 decades1.
Long-therm outcomes determine the key social, medical
and economic impact of this disease. Disease-modifying
treatments (DMTs) are prescribed to delay disease pro-
gression and to protect a patient’s functional capability.
The paradigm of pathogenesis of multiple sclerosis (MS)
is still a topic of discussion and debate among controver-
sial positions. The currently established stance in which
MS is an autoimmune process led by an inflammatory
demyelinisation disease counters the theory that MS is
actually a neurodegenerative disease, either primary or
associated with age2. Research has shown that there is
support for both scenarios and that a »demyelinisation
syndrome« implies various types of damage, which sug-
gests a range of mechanisms involved in their develop-
ment. In addition to focal demyelinisation, MS is charac-
teristic due to the diffuse appearance of damage to nor-
mal-appearing white matter (NAWM), axonal damage
that can be of varying intensity, and brain atrophy3,4. The
acute phase of the disease is marked by focal demyeli-
nisation with post-contrast imbibitions, while the pro-
gressive phase of the disease is dominated by atrophy of
the brain and loss of axons, which is correlated to the de-
gree of neurological disability. The relapsing-remitting
form of multiple sclerosis is classically considered a bi-
phasal disease with relapses of a potentially reversible
phase of the disease, correlated with inflammatory de-
myelinisation and a secondary potentially irreversible
phase of the disease that is marked by critical axon loss.
The inflammatory changes are less pronounced in the
later phases, though the disease shows increasing pro-
gression. This dissociation between the intensity of in-
flammation and the progressive development of neuro-
logical disability represents the inflammatory-neurode-
generative paradox that is characteristic of MS, and
which marks the transition into the irreversible phase of
the disease. Numerous clinical, neuropathological and
neuroimaging studies have aimed to define the mutual
associations of the inflammatory and progressive phases
of MS. It has long been known that early relapse impacts
the long term disability in MS, though there are still un-
certainties and ambiguities as to the trigger that swit-
ches relapsing-remitting MS into the secondary progres-
sive form5. Some epidemiological studies of the natural
course of MS have shown certain limitations regarding
the influences of the inflammatory phase of the disease
on the progression of disability, giving the conclusion
that the relapsing and neurodegenerative phases of MS
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are mutually independent. In such a case, not only the
number of relapses can have predictive value in the de-
velopment of invalidity; age, sex, residual deficit after
the first relapse, time to the second relapse, the total
number of relapses in the first two years and the dura-
tion of the inter-relapse interval can also be valuable
indicators6–9. Though the position on the influence of re-
lapses on the progression of the disease is controversial,
it is unquestionable that MS ultimately results in an un-
sustainable progressive phase with permanent invalidity
of the patient10. The dual concept of the pathogenesis of
MS significantly determines the start of treatment. In
secondary progressive MS, the therapy options have been
exhausted and have been reduced exclusively to the
treatment of symptoms. Therefore, it is of exceptional
importance to commence the treatment of MS »on time«
in order to prevent, or at least delay, the undesirable final
outcome of the disease. The optimal »therapy window«
for MS implies the stage of the clinically isolated syn-
drome (CIS) and the early relapsing-remitting phase.
Treat from CIS onset – Yes or No?
The early application of immunomodulation therapy
brings with it a series of challenges: from when to begin
and when to possible cease therapy, which therapy strat-
egy is optimal for the individual patient, when and how
to modify the therapy in the case of an unsatisfactory
therapeutic response to the basic immunotherapy? The-
se are all challenges we face in our daily work, and these
demand careful assessment based on an individual and
proactive approach that is adapted to meet the needs of
each individual patient (»patient unique approach«). When
to begin with the application of immunomodulation ther-
apy: in the phase of the clinically isolated syndrome, or
upon the onset of clinically definitive MS? This question
has been a subject of debate and there is no definitive
consensus. There are two opposing positions: in the first,
treatment should begin immediately after determination
of a clinical syndrome suggestive of MS, while the second
position can best be described by the phrase »wait and
see«, which implies not introducing DMT immediately,
and instead waiting and monitoring the development of
events. It is difficult to say which position represents the
right approach. The central questions in this context are
(I) for how many of CIS patients can we anticipate a fa-
vourable natural history? (II) can these patients with a
good prognosis be identified early? (III) how many dis-
ease signals are needed before a therapy should be initi-
ated? and (IV) how do we assess the long-term benefits,
risks, and burden of available therapies?11 In daily prac-
tice, cultural differences and, in particular, economic lim-
itations may also influence how we finally counsel a pa-
tient, since the potentially high treatment costs repre-
sent a significant economic burden for both patients and
payers.12 The criteria for the application of immuno-
modulation therapy after the appearance of a clinically
isolated syndrome is based on assessment of the risk of
CIS conversion into clinically definitive MS. Clinical stu-
dies whose results have shown that the risk of CIS con-
version into clinically definitive MS is significantly less
in groups of patients who received basic immunotherapy
(IFN-betw and GA) in comparison with the placebo
groups. This suggested that the application of immu-
nomodulation therapy should begin already at the stage
of the clinically isolated syndrome (Table 1)13–17.
Considering that the decision to start immunothe-
rapy has great repercussions on the continued monitor-
ing of patients with MS, it is very important to properly
select patients prior to the start of therapy, in a way that
identifies patients with a high risk of conversion of CIS
into clinically definitive RRMS. These are patients with
severe initial symptoms and multifocal onset in the first
clinical episode, especially in cases with unsatisfactory
therapeutic response to pulse corticosteroid therapy, and
patients without signs of clinical activity of the disease
but for whom continuous monitoring of radio-morpho-
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TABLE 1
CIS STUDIES WITH EVIDENCE LEVEL A
Study Population Treatment groups Result
ETOMS (2001) 308 CIS and suggestive MRI 154 IFNb-1a 22mg s.c./week
154 placebo
Conversion risk at 2 years
Placebo 45%
IFNb-1a 34%
CHAMPS (2001) 383 CIS and ³2 lesions MRI
193 IFNb-1a 30 mg i.m./week
190 placebo
Conversion risk at 2 years
Placebo 39%
IFNb-1a 21%
BENEFIT (2006) 468 CIS and ³2 lesions MRI
292 IFNb-1b 250 mg s.c./2 days
176 placebo
Conversion risk at 2 years
Placebo 45%
IFNb-1b 28%
PRECISE (2009) 481 CIS and suggestive MRI
243 GA 20 mg s.c./day
238 placebo
Conversion risk at 2 years
Placebo 43%
GA 25%
CIS – clinically isolated syndrome; GA – glatiramer acetate; IFNb – interferon-beta
logical (MR) status regularly detects new lesions as proof
of subclinical activity of the disease.
Escalating Immunotherapy
The selection of an optimal therapy strategy that can
modify the course of multiple sclerosis and enable these
patients to live longer lives without significant physical
disability and cognitive dysfunction is a challenge in
treating MS. The two strategic treatments, escalation
and induction therapy, are mutually opposed18. The con-
cept of escalation immunotherapy represents a treat-
ment strategy that gives precedence to drugs with the
best risk/benefit ratio, and if necessary, later sequentially
advances in the treatment pyramid, introducing drugs
with greater strength though usually with greater toxic-
ity, while does not necessarily imply greater efficacy.
First-line drugs in the treatment of relapsing-remittent
MS are beta-interferons and glatiramer acetate (GA).
These are the basic immunotherapy, such that Beta-
feron, Avonex and Copaxone have approved indications
not only in relapsing-remitting MS but also in CIS that is
at high risk for the development of definitive MS. This
treatment concept represents the strategy of choice for
patients with the benign form of RRMS where it is ex-
pected that the disease can be optimally controlled over a
longer time period using the basic immunotherapy.
Natalizumab (Tysabri) is the first monoclonal anti-
body specially intended for the treatment of relapsing-re-
mitting MS. It acts by binding on the alpha-4 integrated
adhesion molecule in the endothelium of the brain’s
blood vessels in such a way as to block the binding of lym-
phocytes and their entrance into the central nervous sys-
tem. The effectiveness of natalizumab was tested in two
large multi-centric studies. In the AFFIRM study, the use
of natalizumab as a monotherapy resulted in a signifi-
cant decline in the annual relapse rate (ARR), reduced
disease progression and a reduction in the number of ac-
tive lesions shown on an MRI19. The impressive results of
this AFFIRM study accelerated the approval procedure
for the drug by the US Food and Drug Administration
(FDA) in 2004, however, the initial approval was tempo-
rarily suspended after two cases of progressive multifocal
leukoencephalopathy (PML) were reported in patients
that can received a combined therapy of natalizumab and
Avonex in the SENTINEL study, where the use of nata-
lizumab was tested as an add-on therapy20. However, af-
ter additional careful analyses, natalizumab was re-ap-
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TABLE 2
FIRST-LINE DRUGS AND APPROVED INDICATIONS
Drug Dose Route Indications
IFNb-1b
(Betaferon)
250 mg every other day s.c.





30 mg 1x a week i.m.




22 or 44 mg 3x a week s.c.




20 mg daily s.c




14 mg daily Oral RRMS
CIS – clinically isolated syndrome; i.m. – intramuscular; MS – multiple sclerosis; RRMS – relapsing-remitting multiple sclerosis; s.c. –
subcutaneous; SPMS – secondary progressive multiple sclerosis; *Teriflunomide (Aubagio) is approved since August 2013. Second-line
drugs are natalizumab, fingolimod, mitoxantrone and alemtuzumab.
TABLE 3
SECOND-LINE DRUGS AND APPROVED INDICATIONS
Drug Dose Route Indications
Mitoxantrone
(Novantrone)
12 mg/m2 body surface area
every 3 months
i.v.
Highly active RRMS or SPMS with fre-




300 mg every 4 weeks i.v.
RRMS patients who have not responded
to a full and adequate course of IFNb
Fingolimod (Gilenya) 0.5 mg daily oral Rapidly evolving aggressive RRMS
Alemtuzumab (Lemtrada)*
12 mg daily for 5 days at month 0,
12 mg daily for 3 days at month 12
i.v. Rapidly evolving aggressive RRMS
*Alemtuzumab (Lemtrada) is approved since September 2013 by the EMA.
proved in 2006, though exclusively as a monotherapy line
drug in patients who did not have a satisfactory response
to basic immunotherapy. The most severe adverse reac-
tion to natalizumab treatment is progressive multifocal
leukoencephalopathy (PML) – a fatal, opportunistic brain
infection caused by the JC virus. Its risk is estimated at 1
in 1000, and therefore patients who are potential candi-
dates for this therapy must be carefully selected, with
particular attention to previous immunomodulation or
immunosuppressive therapies prior to the appropriate
wash out period21. It is recommended that the use of
immunomodulation drugs be ceased one month before,
and immunosuppresants at least six months before the
start of use of natalizumab.
Fingolimod (Gilenya) is the first immumomodulator
that was approved by the FDA in 2010 as a first-line drug
for the treatment of relapsing-remitting MS. The Euro-
pean Medications Agency approved fingolimod in 2011,
but as a second-line drug intended for patients with ac-
tive RRMS who had an unsatisfactory therapeutic re-
sponse to basic immunotherapy. The efficacy of fingo-
limod was tested in two large multi-centric studies. The
FREEDOMS study investigated the effect of fingolimod
in comparison to a placebo, while the TRANSFORMS
study assessed the effectiveness of varying doses of fingo-
limod in comparison to the i.m. drug interferon-beta 1a
(Avonex)22,23. The results of the study proved the superi-
ority of fingolimod in comparison to the placebo, and of
the Avonex group in relation to the primary and second-
ary indicators of treatment outcome, which consist lar-
gely of a reduced rate of relapse at an annual level, a re-
duced rate of progression of disability, and significant
reduction of the number of active lesions shown in the
MRI.
Mitoxantrone (Novantrone) is a cytotoxic drug that
induces apoptosis of the lymphocytes, and it was ap-
proved in the treatment of aggressive RRMS as a sec-
ond-line drug following the results of Phase III MIMS
trials24. This multi-centric, placebo-controlled study in-
cluded 194 subjects that were treated every three months
over a two-year period, and the results showed the supe-
riority of mitoxantron in comparison with the placebo
group when applied in a dose of 12 mg/m2 body area. The
efficacy of mitoxantrone was measured using combined
outcome indicators, including changes in the EDSS score
and mobility index after two years in comparison with
initial values, the number of treated relapses, and the
time to the first treated relapse. However, mitoxantrone
is a cardiotoxic drug, which certainly casts a shadow on
its applicability, as it requires strict supervision of the pa-
tient’s cardiac status25,26. In that sense, during treat-
ment with mitoxantrone, patients require permanent ul-
trasound and isotope controls of the functioning of the
left ventricle, and if the ejection fraction is <50%, this
represents a contraindication for the use of mitoxan-
trone. The second important risk of mitoxantrone ther-
apy is the development of acute myeloic leukaemia,
which thus requires frequent controls of the complete
blood screen, not only during therapy, but also several
years after the completed therapy, considering the cumu-
lative toxic effect of mitoxantrone27. For this reason, the
total cumulative dose may not exceed 100 mg/m2 body
area. The risk of gonadal dysfunction increases with age;
in women this manifests as amenorrhea, in males as ir-
regular spermiogram28.
The current therapeutic algorithm for risky CIS and
relapsing-remitting MS implies commencing treatment
with the first-line therapy and, in the case of an unsatis-
factory therapeutic response, to advance in the therapy
pyramid until optimal control and stabilization of the
disease is achieved. The first step in the application of
this strategy may be to switch from one drug to another
within the first-line. The typical approach is, for exam-
ple, to replace a low dose IFN with a higher dose, or to
administer it in a greater frequency, as there is B level ev-
idence that indicates the benefits of increasing the dose
and frequency of administration of IFN29. The second
possibility in the case of an unsatisfactory clinical re-
sponse or intolerance to therapy is to replace the IFN
therapy with glatiramer acetete. The theoretical basis for
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TABLE 4
NATALIZUMB, BENEFIT VS. RISK – EVALUATION
BENEFITS
Established in clinical trials:
AFIRM, N=942, monotherapy
– 68% reduction in ARR
– 42% reduction in disability
progression
















PML progressive multifocal leukoencephalopathy
TABLE 5
FINGOLIMOD, BENEFIT VS. RISK – EVALUATION
BENEFITS
Established in clinical trials:
FREEDOMS, N=1033, vs. placebo
– ARR reduced
– EDSS at 2 years reduced
– risk of disability progession
reduced













ARR, annualized relapse rate; EDSS, expanded disability status
scale
this change stems from the alternate action mechanism.
Several trials with C level evidence have been conducted
in which IFNb-1a is replaced with glatiramer acetate and
vice versa. One such trial indicated that patients for
whom IFNb-1a treatment was ineffective, a switch to
glatiramer acetate resulted in a significant reduction in
the number of relapses30.
Once the first-line therapeutic options are exhausted,
if there is still a lack of a satisfactory response, a sec-
ond-line drug should be introduced as a monotherapy.
Second-line therapy should begin with natalizumab or
fingolimod, while mitoxantron should remain the last
possible option due to its high toxicity that limits the
therapy period.
For patients with frequent relapses and constant clin-
ical deterioration, despite first-line or second-line immu-
nomodulation and repeated application of pulse cortico-
steroid therapy, the option that is applied without delay
is intensive immunosuppression with cyclophosphamide
or mitoxantron, or even autotransplant of bone marrow
stem cells, which marks the transition into third-line
therapy in escalation immunotherapy (Figures 1 and 2).
In that situation of the escalation of immunotherapy, the
drug that is regularly given is halted, and intensive
immunosuppression begins, following a comprehensive
evaluation of patient activity in order to determine the
new starting position. This will enable an assessment of
the response to the new therapy31.
Several studies have shown the benefit of mitoxan-
trone on disease activity in patients with suboptimal re-
sponse to first-line DMD32.
Criteria of DMT Response
The therapeutic response to immunomodulation
treatment can be optimal, sub-optimal and unsatisfac-
tory. An optimal therapeutic response is seen when pa-
tients receiving basic immunotherapy show no clinical or
radiological activity. These are typically called »full re-
sponders«. They remain on basic immunotherapy for as
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Fig. 1. Treatment algorithm of RRMS (The Barcelona approach)33.
In the case of suboptimal response or intolerance to first-line the-
rapies: (a) consider switching among first-line therapies, (b) con-
sider second-line therapies, In the case of sub-optimal response
or intolerance to second line therapies: (c) consider changing to
third-line therapies. *Fingolimod is approved in the USA as first
line.
Fig. 2. Treatment algorithm of RRMS (The Latin American approach)34. BMT – bone marrow transplant.
long as the disease is clinically and radiologically stable.
Non-responders are patients lacking a therapeutic re-
sponse to basic immunotherapy, which is seen in both ra-
diological and clinical activity. The characteristic of sec-
ondary non-responders is that there is a »breakthrough«
of the disease after a varying period of satisfactory ther-
apy response, in which the disease stagnated both clini-
cally and radiologically. Non-responders generally re-
quire adjustment of the therapy, either within the first-
-line therapy, or switching to second-line therapy, de-
pending on the level of disease activity.
The definition of a sub-optimal response to DMT is
somewhat debated, considering that it implies an in-
creased level of disease activity that can be either accept-
able or not acceptable. For this reason, it is important to
assess patients with a sub-optimal response to DMT to
determine whether the disease activity is significant
enough to require a change in the therapy by switching
to a stronger but more toxic drug, or whether it is mild
enough to retain the status quo. The monitoring algo-
rithm for patients on immunomodulation therapy im-
plies a clinical and radiological evaluation of the status in
control intervals of 6 to 12 months. In the case of a stable
clinical status with the absence of radiological activity, it
is advised that the current therapy be continued with
further clinical and MR evaluations. If the control MR
exam confirms radiological activity with greater than
two active lesions, it is necessary to determine whether
the lesions are »clinically mute« or whether the radiolog-
ical activity is accompanied by clinical activity as a re-
lapse of the disease or progression of neurological disabil-
ity. The appearance of clinically mute active lesions does
not require a change to the DMT, but instead only clini-
cal monitoring with frequent clinical and MR assess-
ments. On the contrary, the appearance of radiological
activity accompanied by clinical activity requires a chan-
ge in the DMT. Sub-optimally controlled MS with an un-
acceptable increase in the disease activity level requires a
change in therapy. It should be stressed that for now,
there are no testing results with a first degree proof level
that would support the application of escalation immu-
notherapy in patients with a sub-optimal response, the-
refore, it is necessary to bear in mind that any decision
made in that stage of the therapeutic algorithm will be
based on less concrete evidence that those made at the
start of treatment. Keeping these limitations in mind,
the approach in selecting the optimal strategy should,
above all, be individual, based on the age at which the
disease began and the level of disease activity during ba-
sic therapy, and also on the different mechanisms of drug
activity.
Induction Therapy
The concept of escalation therapy has both advan-
tages and disadvantages. The advantages of this strategy
are that the treatment begins with immunomodulation
drugs with the most favourable risk-benefit ratio. This
implies good tolerance of the treatment, without signifi-
cant adverse reactions. However, the lack of this strategy
is that it most often does not ensure optimal disease con-
trol. It would be excessive to expect that the basic im-
munotherapy can fully halt disease activity. The state in
which the disease is active and sub-optimally controlled,
despite the immunomodulation therapy, increases the
risk of lasting neurological disability. Recognition of a
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TABLE 6
MITOXANTRON, BENEFIT VS. RISK – EVALUATION
BENEFITS
Established in clinical trials:
MIMS, N=194, (2002.)
– EDSS at 2 years reduced
– ambulation index at
2 y. reduced










– male: decreased sperm count








»Reset« of the immune system
to prevent epitope spreading
and control inflammatory disease
activity more effectively than
immune modulation.
Prevention of early irreversibile
damage.
Better risk/benefit ratio when













Scavenger macrophagesFig. 3. DMT response.
suboptimal response to therapy and the timing and
choice of therapy switches in patients with breakthrough
disease remain challenging for clinicians who treat MS
patients. An alternative to escalation strategy, the con-
cept of induction therapy is recommended for patients
with more aggressive disease and implies short-term in-
tensive immunosuppresive therapy as the initial therapy
followed by long-term maintenance therapy with an im-
munomodulatory drug. Early immunosuppression might
control inflammatory disease activity in RRMS more ef-
fectively than immunemodulation and therefore could
better preserve brain function and control disease pro-
gression. The advantage of early immunosuppressive
therapy is actual the »resetting« of the immunological
system to prevent irreversibile damage and the phenom-
enon of epitope spreading among others which results in
better control of disease activity. Ultimately, this pre-
vents early irreversibility of damage.
Induction therapy, however, has disadvantages that
can be potentially risky for patients, primarily due to the
increased toxicity of immunosuppressive therapy. This
pertains to the increased risk of infection and malig-
nance, followed by leukopaenia, gonadal dysfunction and
cardiomyopathy. Immunosuppressive therapy can have
an undesirable inhibitory effect on remyelinisation.
Considering the potential risk of induction therapy, it
must be carefully planned. It is most important to prop-
erly select patients who are potential candidates for this
therapeutic approach, based on the clinical and radiologi-
cal prognostic risk factors of early neurological disability.
The clinical parameters that can have a predictive value
in early phases of MS, as they enable identification of pa-
tients with a likelihood of poor disease outcome, are:
multifocal start of the disease with symptoms of motor
and sensory deficiency and a loss of sphincter function
with incomplete recovery after the first episode, followed
by a high relapse rate and short inter-relapse interval,
and the development of neurological disability within the
first five years. The MR prognostic factors of a poor dis-
ease outcome are a large number of lesions with persis-
tent radiological activity, and the presence of lesions in
the infratentoral and spinal regions.
Those patients presenting with several of these clini-
cal and radiological features are likely to be at higher risk
for early disability, either secondary to accumulating re-
lapse related disability or earlier evolution into the sec-
ondary progressive MS stage35. Different prognostic fac-
tors in early MS are summarized in Table 836,37.
Patients transitioning to more progressive disease
may be nearing the end of the window of opportunity for
immunomodulatory treatment and may require inter-
vention with more aggressive agents38. Mitoxantrone is
approved for worsening RRMS and should be considered
in such patients given its proven efficacy for reducing
disease activity in this patient population.
Conclusion
Considering that the currently available basic immu-
notherapy is only partially effective, and that in a share
of patients, the disease progresses despite treatment, the
question arises as to which therapeutic approach is the
right one in treating RRMS – escalation or induction?
Both treatment strategies may be valuable options, in
which the concept of induction therapy is recommended
for patients with a more aggressive form of the disease
which already presents a high relapse rate with multi-fo-
cal onset and rapid development of neurological disabil-
ity even in the earliest phases. The current escalation ap-
proach in active MS may leave patients with suboptimal
disease control for several years before treatment is ad-
vanced to more potent agents. This may lead to a missed
window of opportunity to prevent permanent disability
resulting from irreversibile axonal loss.
Starting the most effective treatment initially and
move into well-tolerated maintenance when disease ac-
tivity is controlled may be a better approach. This treat-
ment concept is potentially more risky for the patient
due to the possible serious adverse reactions from immu-
n osuppressive therapy. However, it represents the strat-
egy of choice in aggressive forms of MS where conversion
into the secondary progressive form of the disease can be
expected very early, which narrows the possible treat-
ment for these patients.
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TABLE 8
CLINICAL AND MRI PROGNOSTIC FACTORS IN EARLY MS
BETTER PROGNOSIS POORER PROGNOSIS
Monofocal onset Multifocal onset
Onset with optic neuritis or isolated sensor symptoms Onset with motor, cerebellar, or bladder/bowel symptoms
Low relapse rate in first 2–5 years High relapse rate in first 2–5 years
Long interval to 2nd relapse Short inter-attack latency
No or low disability at 5 years Disability at 5 years
Low lesion load on MRI
Abnormal al MRI ³2 contrast
Lesions ³9 T2 lesions
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TREBA LI MULTIPLA SKLEROZA BITI TRETIRANA ESKALACIJSKOM ILI
INDUKCIJSKOM TERAPIJOM?
S A @ E T A K
MS je kroni~na, progresivna bolest ~iji dugoro~ni ishodi determiniraju klju~ne dru{tvene, medicinske i gospodarske
utjecaje ove bolesti. Terapije za modificiranje bolesti (DMT) za multiplu sklerozu su pripisani za odga|enje progresije
bolesti i za za{titu pacijentove funkcionalne sposobnosti. Pojmovi eskalacije i indukcije imunoterapije kod MS predstav-
ljaju razli~ite terapeutske strategije za lije~enje MS-a. Obje strategije mogu biti vrijedne opcije za pacijente koji po~inju
sa DMT terapijom, no indukcijska terapija se usredoto~uje na pacijente sa vrlo agresivnim tijekom MS-a. Koriste}i
pristup jedinstven pojedinom pacijentu za odabir lije~enja, MS mo`e biti u~inkovito kontrolirana bolest i mo`e odgoditi
ili ~ak sprije~iti razvoj sekundarno progresivne MS.
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